The effect of anti-PD1 and anti-PDL1 on the cytokine profile and immune system
JSHS · 2020
Overview
Programmed cell death -1 (PD-1) is an inhibitory receptor expressed on a variety of immune cells that provides a checkpoint against autoimmunity. The binding of PD-1 to its ligand, PD-L1, inhibits T cell function, proliferation, and cytokine production, and promotes apoptosis. Some cancer cells express high levels of PD-L1 and use this mechanism to evade attack. Immune checkpoint inhibitors, anti-PD1 and anti-PDL1, block this binding and allow Tcells to attack cancer cells. However, these treatments have varying efficacy and more than 27% of patients experience adverse effects (Gong et al., 2018). This indicates that anti-PD1 and anti-PDL1 alter the healthy immune system. The goal of this study was to examine the effects of anti-PD1 and anti-PDL1 on the cytokine profile and immune system composition of healthy wild type mice to identify possible biomarkers for an adverse reaction to treatment. The cytokine profile of the serum and the immune landscape of the spleen of the mice treated with either anti-PD1, antiPDL1, or a control isotype were examined. These studies indicated that among the several cytokines tested, B Lymphocyte Chemoattractant (BLC), a chemotactic cytokine for Bcells, and TIMP Metallopeptidase Inhibitor 1(TIMP-1), a signaling molecule that influences cell growth, apoptosis, and differentiation, were upregulated following anti-PD1 treatment. Additionally, immunophenotyping studies indicated that Bcells and CD4+ and CD8+ Treg cells were up-regulated by treatment with both anti-PD1 and anti- PDL1. The adverse effects and varying efficacy of anti-PD1 and anti-PDL1 may be linked to these changes in the healthy immune system. Reference List: Gong, Jun, et al. “Development of PD-1 and PD-L1 Inhibitors as a Form of Cancer Immunotherapy: a Comprehensive Review of Registration Trials and Future Considerations.” Journal for Immunotherapy of Cancer, BioMed Central, 23 Jan. 2018. Accessed on June 5, 2019.
Competition history
- JSHS 2020
Resources
Related projects
ISEF · 2017
The Mutagenesis of the PD-L1 Inhibitory Ligand to Identify the Binding Site of the Novel PD-L1/B7-1 Pathway
ISEF · 2016
The Effect of Targeted Inhibitors on Melanoma Tumor Immunity
ISEF · 2023
Immune Checkpoint Regulation in Molecular Subtypes of Endometrial Cancer: Expression of PD-L1 and PD-1
ISEF · 2015
On a Mission: Rescuing T-Cells to Fight Cancer
ISEF · 2022
CD160 in Cytotoxic T Cell Exhaustion and Its Effect on PD-1 Blockade Cancer Immunotherapy
ISEF · 2022
Identifying Small Molecule Inhibitors of Programmed Cell Death 1 for Cancer Immunotherapy Using Pharmacophore-Based Virtual Screening
ISEF · 2023
The Effect of Immune Checkpoint Inhibitor Ipilimumab on the Development and Proliferation of Breast Cancer Stem Cells
ISEF · 2018
Designing a Modified HAC-PD-1 to Antagonize PD-L2 for the Improvement of Cancer Immunotherapy
Closest projects by meaning, across every fair and year in the corpus.